Antimicrobial peptide LL-37 promotes YB-1 expression, and the viability, migration and invasion of malignant melanoma cells.
Jia. Jinjing J; Zheng. Yan Y; Wang. Wei W; Shao. Yongping Y; Li. Zhengxiao Z; Wang. Qiong Q; Wang. Yuan Y; Yan. Huling H
Key Findings
- LL‑37 raises YB‑1 levels in melanoma cells
- Higher LL‑37 makes melanoma cells proliferate, migrate, and invade more
- Blocking NF‑κB reduces the LL‑37‑driven YB‑1 increase
Practical Outcomes
- For biohackers, this suggests LL‑37 isn’t a safe supplement for anti‑aging or performance purposes, especially if you have a history of skin cancer or risk factors. Avoid using LL‑37 until more safety data are available.
Summary
The study found that the antimicrobial peptide LL‑37 can make melanoma cancer cells grow and spread faster by boosting a protein called YB‑1 and activating a cell‑signaling pathway (NF‑κB).
Abstract
The cathelicidin antimicrobial peptide, LL-37, is a multifunctional peptide with a broad spectrum of antimicrobial activities, such as chemotaxis and neutralizing endotoxins. Previous studies have demonstrated that it LL‑37 serves a functional role in the development of numerous types of cancer including ovarian, breast, prostate and lung cancer. However, its role in the development of malignant melanoma (MM) remains unclear. To determine the role of LL‑37 and the potential interaction with Y-box binding protein 1 (YB‑1) in MM, RNA interference, western blot, reverse transcription-quantitative polymerase chain reaction, MTT and Transwell assays were performed. The current study demonstrated that LL‑37 induced YB‑1 expression, and increased tumor cell proliferation, migration and invasion of A375 and A875 MM cell lines. In addition, inhibition of nuclear factor‑κB (NF‑κB) attenuated LL‑37‑induced YB‑1 expression. These results demonstrate that, through the upregulation of YB‑1 expression and the activation of the NF‑κB signaling pathway, LL‑37 may promote the malignant progression of MM cells in vitro.
Study Information
pubmed
2016
2016-12-02T00:00:00.000Z
10.3892/mmr.2016.5978
21
43